摘要
目的探讨替吉奥(S-1)联合奥沙利铂治疗晚期胃癌的临床效果及对血清基质金属蛋白酶-2(MMP-2)、MMP-9、糖类抗原125(CA125)、癌胚抗原(CEA)水平的影响,并分析该化疗方案的安全性。方法选取2013年6月至2015年1月收治的140例晚期胃癌患者进行回顾性分析,其中70例患者采用S-1联合奥沙利铂治疗(观察组),70例患者采用5-氟尿嘧啶+亚叶酸钙+奥沙利铂治疗(对照组)。对比两组患者的化疗效果、血清MMP-2、MMP-9、CA125、CEA水平、KPS评分及毒副作用。结果观察组的缓解率41.43%显著高于对照组的25.71%(P<0.05);观察组的总有效率88.57%与对照组的81.43%比较,差异无统计学意义(P>0.05);治疗前,两组患者的MMP-2、MMP-9、CA125、CEA水平差异无统计学意义(P>0.05);治疗后,观察组的MMP-2、MMP-9、CA125、CEA水平显著低于对照组(P<0.05);治疗前,两组患者的KPS评分差异无统计学意义(P>0.05);治疗后,观察组的KPS评分显著高于对照组(P<0.05);观察组的恶心呕吐发生率(31.43%)显著低于对照组(51.43%,P<0.05)。结论 S-1联合奥沙利铂治疗晚期胃癌较5-氟尿嘧啶+亚叶酸钙+奥沙利铂治疗的效果更好,能显著降低MMP-2、MMP-9、CA125、CEA水平,毒副作用发生率更低。
Objective To investigate the clinical effect and safety of S-1 and oxaliplatin in the treatment of advanced gastric cancer,and the levels of serum matrix metalloproteinase-2（ MMP-2）,MMP-9,carbohydrate antigen 125（ CA125） and carcinoembryonic antigen（ CEA）. Methods A total of 140 cases of patients with advanced gastric cancer diagnosis and treatment of cancer were retrospectively analyzed from June 2013 to January 2015,of which 70 cases were treated with S-1 combined with oxaliplatin in the treatment（ observation group）,70 patients with 5-fluorouracil plus leucovorin and oxaliplatin treatment（ control group）,the effect of chemotherapy and serum MMP-2,MMP-9,CA125,CEA level,KPS score and adverse reaction were compared between the two groups. Results The remission rate of the observation group41. 43% was significantly higher than that of control group 25. 71%（ P〈0. 05）. The total efficiency of observation group 88. 57% and 81. 43%in the control group had no significant difference（ P〈0. 05）. The MMP-2,MMP-9,CA125,CEA level difference before treatment in the two groups had no statistically significant difference（ P〈0. 05）. After treatment,MMP-2,MMP-9,CA125 and CEA in the observation group were significantly lower than that of control group（ P〈0. 05）. Before treatment,there was no significant difference in KPS score of the two groups（ P〈0. 05）. After treatment,KPS scores of the observation group were significantly higher than that of control group（ P〈0. 05）. The incidence of nausea and vomiting in observation group（ 31. 43%） was significantly lower than that of the control group（ 51. 43%）（ P〈0. 05）.Conclusion The efficacy of S-1 combined with oxaliplatin in the treatment of advanced gastric cancer is better than that of 5-fluorouracil ＋calcium folate ＋ oxaliplatin,and the incidence of adverse reaction is lower.
作者
王婵
朱武
王峰
汪涛
WANG Chan;ZHU Wu;WANG Feng(Department of Clinical Laboratory;Department of Digestive Disorders,Ankang Hospital of Traditional Chinese Medicine,Ankang Shaanxi 725000,China.)
出处
《临床和实验医学杂志》
2018年第15期1630-1633,共4页
Journal of Clinical and Experimental Medicine
